Poly(DL-lactide-co-glycolide) microporous microsphere-based depot formulation of a peptide-like antineoplastic agent

Area of Science:

• Biomaterials Science
• Drug Delivery Systems
• Oncology

Background:

• Biodegradable polymers like poly(DL-co-glycolide) (PLGA) are crucial for advanced drug delivery.
• Developing sustained-release formulations for anti-cancer agents like bleomycin (BLM) is essential for improving therapeutic outcomes.
• Melanoma B16F1 murine solid tumors provide a relevant model for evaluating anti-neoplastic therapies.

Purpose of the Study:

• To formulate and evaluate a poly(DL-co-glycolide) (PLGA)-based microspheric depot system for bleomycin (BLM).
• To assess the in-vivo efficacy of the BLM-loaded PLGA microspheres in a murine melanoma model.
• To investigate the pharmacokinetic and pharmacodynamic profile of the injectable drug depot.

Main Methods:

• Formulation of poly(DL-co-glycolide) (PLGA) microspheres using a water-in-oil-in-water (W/O/W) emulsion-solvent evaporation technique.
• In-vitro characterization of the microparticulate delivery systems.
• Subcutaneous injection of drug-loaded microspheres in C57BL/6J mice bearing melanoma B16F1 tumors for in-vivo evaluation.

Main Results:

• The poly(DL-co-glycolide) (PLGA)-based microspheres successfully formed an injectable drug depot.
• In-vivo studies demonstrated retarded tumor growth kinetics, indicating improved pharmacodynamic efficacy.
• Preliminary pharmacokinetic analysis revealed controlled release of bleomycin (BLM) over the study period.

Conclusions:

• Poly(DL-co-glycolide) (PLGA) microspheres represent a feasible approach for creating biodegradable, injectable, depot-forming systems.
• This system offers a promising strategy for the long-term administration of anti-neoplastic agents.
• The developed microspheric depot system enhances the therapeutic potential of bleomycin (BLM) in cancer treatment.